![Pavel Khrimian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Pavel Khrimian
Sociétés | Poste | Début | Fin |
---|---|---|---|
Deka Biosciences, Inc.
![]() Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | Fondateur | 01/01/2019 | - |
Corporate Officer/Principal | 01/01/2019 | - |
Historique de carrière de Pavel Khrimian
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Deka Biosciences, Inc.
![]() Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | Health Technology |
- Bourse
- Insiders
- Pavel Khrimian
- Expérience